Mumtaz Score for Readmission in Cirrhosis

The Mumtaz Score predicts 30‑day readmission risk in decompensated cirrhosis using demographics, comorbidities, complications, and key in‑hospital interventions 1 [Level II evidence].

Age, years
≥ 65040-64+418-39+7
Primary payer
Self-pay-3No charge or other-1Private insurance0Medicare+4Medicaid+5
Elixhauser Comorbidity Index
< 30≥ 3+2
Non-alcoholic etiology of cirrhosis
No0Yes+2
Ascites
No0Yes+5
Hepatic encephalopathy
No0Yes+4
Variceal bleeding
Yes-7No0
Hepatocellular carcinoma
No0Yes+3
Paracentesis during admission
No0Yes+4
Hemodialysis during admission
No0Yes+7
Disposition
Transfer-1Routine0Home health care+1Against medical advice+10

Indikationen

Used in hospitalized adults with decompensated cirrhosis at discharge to estimate 30‑day readmission risk based on demographics, decompensation features, and in‑hospital interventions. Derived from 123,011 patients and externally validated 1 [Level II evidence]. Helps stratify into low (<20%), medium (20–30%), and high (>30%) readmission risk to guide closer follow‑up and targeted post‑discharge interventions.

Hinweise & Vorsichtsmaßnahmen

Identifies 30‑day readmission risk in decompensated cirrhosis but has modest discrimination (c‑statistic ≈0.64–0.70) and relies on administrative data with limited clinical granularity 1 [Level II evidence].
• Overweights inpatient complications (HE, infections, HD) and may misclassify compensated or atypical phenotypes.
• Not externally validated in contemporary cohorts and may underperform across etiologies, frailty levels, and ambulatory settings.